Article Sidebar

PDF (Tiếng Việt)
Published: 2025-10-31
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v195i10.3942
Issue
Vol. 195 No. 10 (2025)
Section
Các bài báo
How to Cite
Tú, T. A., Tuấn, P. L. A., Thuý, N. T., Hùng, K. Đình, Hằng, T. T. T., Lợi, L. P., & Khánh, T. V. (2025). 33. Determination of miRNA-106a expression levels in glioma patients. Journal of Medical Research, 195(10), 296-304. https://doi.org/10.52852/tcncyh.v195i10.3942

33. Determination of miRNA-106a expression levels in glioma patients

Truong Anh Tu, Pham Le Anh Tuan, Nguyen Thu Thuy, Kieu Dinh Hung, Tran Thi Thuy Hang, Luu Phuc Loi, Tran Van Khanh

Main Article Content

Abstract

Gliomas originate from glial cells in the brain and are characterized by high invasiveness and frequent recurrence after treatment. Recent studies have highlighted the role of microRNAs (miRNAs) in regulating tumor development and progression. Among them, miR-106a has shown potential in suppressing proliferation, invasion, and promoting apoptosis in glioma cells. This study aimed to determine the expression level of miR-106a in the peripheral blood of glioma patients and its association with certain clinical features. Plasma samples from 63 postoperative glioma patients and 63 healthy individuals matched for age and gender were analyzed using Realtime-PCR. Results showed that miR-106a expression in the glioma group (0.17 ± 0.20) was significantly lower than in the control group (0.50 ± 0.71), with p < 0.001. miR-106a levels tended to decrease with higher tumor grades (WHO II: 0.22 ± 0.16; III: 0.15 ± 0.19; IV: 0.17 ± 0.21) although the differences between grades were not statistically significant (p = 0.335); compared with controls, grades III and IV showed significant reductions (p < 0.01 and p < 0.001). These findings suggest that miR-106a may serve as a potential non-invasive biomarker for prognosis and monitoring of gliomas.

Article Details

Keywords

Gliomas, miR-106a, realtime-PCR

References

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. Jun 2016; 131(6): 803-20. doi:https://doi.org/10.1007/s00401-016-1545-1.
2. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. Oct 5 2021; 23(12 Suppl 2): iii1-iii105. doi:https://doi.org/10.1093/neuonc/noab200.
3. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama. Nov 6 2013; 310(17): 1842-50. doi:https://doi.org/10.1001/jama.2013.280319.
4. Verdugo E, Puerto I, Medina M. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun (Lond). Nov 2022; 42(11): 1083-1111. doi: https://doi.org/10.1002/cac2.12361.
5. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. Aug 4 2012; 380(9840): 499-505. doi:https://doi.org/10.1016/s0140-6736(12)60815-0.
6. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. Aug 2014; 15(8): 509-24. doi:https://doi.org/10.1038/nrm3838.
7. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016; 1: 15004. doi:https://doi.org/10.1038/sigtrans.2015.4
8. Ordóñez-Rubiano EG, Rincón-Arias N, Espinosa S, et al. The Potential of miRNA-based Approaches in Glioblastoma: An Update in Current Advances and Future Perspectives. Current Research in Pharmacology and Drug Discovery. 2024: 100193. doi:https://doi.org/10.1016/j.crphar.2024.100193.
9. Zhao S, Yang G, Mu Y, et al. MiR-106a is an independent prognostic marker in patients with glioblastoma. Neuro Oncol. Jun 2013; 15(6): 707-17. doi:https://doi.org/10.1093/neuonc/not001.
10. Zhang Y, Chen J, Xue Q, et al. Prognostic Significance of MicroRNAs in Glioma: A Systematic Review and Meta-Analysis. Biomed Res Int. 2019; 2019: 4015969. doi: https://doi.org/10.1155/2019/4015969.
11. Dai D-W, Lu Q, Wang L-X, et al. Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer. 2013/10/14 2013; 13(1): 478. doi:https://doi.org/10.1186/1471-2407-13-478.
12. Zhang S, Zhang Y, Sun X. Targeting GPR133 via miR-106a-5p inhibits the proliferation, invasion, migration and epithelial-mesenchymal transition (EMT) of glioma cells. Int J Neurosci. Sep 2024; 134(9): 991-1002. doi: https://doi.org/10.1080/00207454.2023.2201873.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. Dec 2001; 25(4): 402-8. doi:https://doi.org/10.1006/meth.2001.1262.
14. So JBY, Kapoor R, Zhu F, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. May 2021; 70(5): 829-837. doi:https://doi.org/10.1136/gutjnl-2020-322065.
15. Daneshpour M, Ghadimi-Daresajini A. Overview of miR-106a Regulatory Roles: from Cancer to Aging. Bioengineering (Basel). Jul 27 2023; 10(8). doi:https://doi.org/10.3390/bioengineering10080892.